186 related articles for article (PubMed ID: 25910424)
1. Mutation of Gly717Phe in human topoisomerase 1B has an effect on enzymatic function, reactivity to the camptothecin anticancer drug and on the linker domain orientation.
Wang Z; D'Annessa I; Tesauro C; Croce S; Ottaviani A; Fiorani P; Desideri A
Biochim Biophys Acta; 2015 Aug; 1854(8):860-8. PubMed ID: 25910424
[TBL] [Abstract][Full Text] [Related]
2. The human topoisomerase 1B Arg634Ala mutation results in camptothecin resistance and loss of inter-domain motion correlation.
D'Annessa I; Tesauro C; Wang Z; Arnò B; Zuccaro L; Fiorani P; Desideri A
Biochim Biophys Acta; 2013 Dec; 1834(12):2712-21. PubMed ID: 24096022
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanism of the camptothecin resistance of Glu710Gly topoisomerase IB mutant analyzed in vitro and in silico.
Tesauro C; Morozzo della Rocca B; Ottaviani A; Coletta A; Zuccaro L; Arnò B; D'Annessa I; Fiorani P; Desideri A
Mol Cancer; 2013 Sep; 12(1):100. PubMed ID: 24004603
[TBL] [Abstract][Full Text] [Related]
4. Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I.
Fiorani P; Bruselles A; Falconi M; Chillemi G; Desideri A; Benedetti P
J Biol Chem; 2003 Oct; 278(44):43268-75. PubMed ID: 12904303
[TBL] [Abstract][Full Text] [Related]
5. Dimethylmyricacene: An In Vitro and In Silico Study of a Semisynthetic Non-Camptothecin Derivative Compound, Targeting Human DNA Topoisomerase 1B.
Ottaviani A; Iacovelli F; Welsch J; Morozzo Della Rocca B; Desideri A; Falconi M; Calcul L; Baker BJ; Fiorani P
Cells; 2022 Nov; 11(21):. PubMed ID: 36359884
[TBL] [Abstract][Full Text] [Related]
6. Structural insight of DNA topoisomerases I from camptothecin-producing plants revealed by molecular dynamics simulations.
Sirikantaramas S; Meeprasert A; Rungrotmongkol T; Fuji H; Hoshino T; Sudo H; Yamazaki M; Saito K
Phytochemistry; 2015 May; 113():50-6. PubMed ID: 25733498
[TBL] [Abstract][Full Text] [Related]
7. The human DNA topoisomerase I mutant Gly717Asp: Higher religation rate is not always associated with camptothecin resistance.
Wang Z; D'Annessa I; Tesauro C; Ottaviani A; Soren BC; Dasari JB; Messina B; Thareparambil A; Fiorani P
Arch Biochem Biophys; 2019 Mar; 663():165-172. PubMed ID: 30653963
[TBL] [Abstract][Full Text] [Related]
8. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine.
Benedetti P; Fiorani P; Capuani L; Wang JC
Cancer Res; 1993 Sep; 53(18):4343-8. PubMed ID: 8395982
[TBL] [Abstract][Full Text] [Related]
9. Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin.
van der Merwe M; Bjornsti MA
J Biol Chem; 2008 Feb; 283(6):3305-3315. PubMed ID: 18056711
[TBL] [Abstract][Full Text] [Related]
10. Alterations in linker flexibility suppress DNA topoisomerase I mutant-induced cell lethality.
Losasso C; Cretaio E; Palle K; Pattarello L; Bjornsti MA; Benedetti P
J Biol Chem; 2007 Mar; 282(13):9855-9864. PubMed ID: 17276985
[TBL] [Abstract][Full Text] [Related]
11. Replacement of the human topoisomerase linker domain with the plasmodial counterpart renders the enzyme camptothecin resistant.
Arnò B; D'Annessa I; Tesauro C; Zuccaro L; Ottaviani A; Knudsen B; Fiorani P; Desideri A
PLoS One; 2013; 8(7):e68404. PubMed ID: 23844196
[TBL] [Abstract][Full Text] [Related]
12. Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity.
Fiorani P; Amatruda JF; Silvestri A; Butler RH; Bjornsti MA; Benedetti P
Mol Pharmacol; 1999 Dec; 56(6):1105-15. PubMed ID: 10570037
[TBL] [Abstract][Full Text] [Related]
13. Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers.
Tesauro C; Graziani G; Arnò B; Zuccaro L; Muzi A; D'Annessa I; Santori E; Tentori L; Leonetti C; Fiorani P; Desideri A
J Exp Clin Cancer Res; 2014 Sep; 33(1):71. PubMed ID: 25227992
[TBL] [Abstract][Full Text] [Related]
14. A pentapeptide signature motif plays a pivotal role in Leishmania DNA topoisomerase IB activity and camptothecin sensitivity.
Prada CF; Alvarez-Velilla R; Diaz-González R; Prieto C; Pérez-Pertejo Y; Balaña-Fouce R; Reguera RM
Biochim Biophys Acta; 2012 Dec; 1820(12):2062-71. PubMed ID: 23000572
[TBL] [Abstract][Full Text] [Related]
15. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
[TBL] [Abstract][Full Text] [Related]
16. Thr729 in human topoisomerase I modulates anti-cancer drug resistance by altering protein domain communications as suggested by molecular dynamics simulations.
Chillemi G; D'Annessa I; Fiorani P; Losasso C; Benedetti P; Desideri A
Nucleic Acids Res; 2008 Oct; 36(17):5645-51. PubMed ID: 18765473
[TBL] [Abstract][Full Text] [Related]
17. DNA topoisomerase I domain interactions impact enzyme activity and sensitivity to camptothecin.
Wright CM; van der Merwe M; DeBrot AH; Bjornsti MA
J Biol Chem; 2015 May; 290(19):12068-78. PubMed ID: 25795777
[TBL] [Abstract][Full Text] [Related]
18. Computational Study of Anticancer Drug Resistance Caused by 10 Topisomerase I Mutations, Including 7 Camptothecin Analogs and Lucanthone.
Mulholland K; Wu C
J Chem Inf Model; 2016 Sep; 56(9):1872-83. PubMed ID: 27564845
[TBL] [Abstract][Full Text] [Related]
19. Sequence selectivity of the cleavage sites induced by topoisomerase I inhibitors: a molecular dynamics study.
Siu FM; Pommier Y
Nucleic Acids Res; 2013 Dec; 41(22):10010-9. PubMed ID: 24021629
[TBL] [Abstract][Full Text] [Related]
20. Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I.
Champoux JJ
Ann N Y Acad Sci; 2000; 922():56-64. PubMed ID: 11193925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
